On April 12, 2022 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, reported it will participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on Thursday, April 14th at 11:30 AM ET (Press release, CNS Pharmaceuticals, APR 12, 2022, View Source [SID1234612104]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For the spotlight event, John Climaco, CEO of CNS Pharmaceuticals will be joined by Key Opinion Leader Samuel A. Goldlust, MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
Dr. Goldlust is a leading Neuro-Oncologist who currently serves as the Pitkin Chair in Neuro-Oncology and Medical Director of the Brain and Spine Institute, John Theurer Cancer Center and an investigator in the Company’s global potentially pivotal study of Berubicin.
Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Anthracyclines, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents, are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The Company is currently conducting a potentially pivotal global study evaluating the efficacy and safety of Berubicin in the treatment of GBM.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.